ADVERTISEMENT

COVID-19

The Good, The Bad, And The Uncertain: Trump’s Second Administration And The Rx Industry

The pharma industry arguably suffered none of the possible downside risks during the first Trump Administration, but its relationship with Biden could not have been much worse. And while sponsors may hope a Trump return could improve their fortunes, having Robert F. Kennedy Jr. supervising the FDA is likely not the prescription they prefer.

The Good, The Bad, And The Uncertain: Trump’s Second Administration And The Rx Industry

The pharma industry arguably suffered none of the downside risks that were possible during the first Trump administration, and their relationship with Biden could not have gone much worse. And while they may hope a Trump return could help their fortunes, having RFK Jr. supervising the FDA is likely not the prescription they want.

Recent Dose Miscalculating Experience In Canada

Canada’s shortage of children’s analgesic/antipyretic OTCs in 2022 as COVID-19 and seasonal flu virus combined to drive stockpiling by consumers. Some poison control centers and hospitals offered recommendations about modifying adult doses to pediatric use.

Gohibic For SARS-CoV-2-Induced ARDS Among Eight New Drugs To Win EMA Nod

Patients in the ICU continue to die from SARS-CoV-2-induced acute respiratory distress syndrome, says InflaRx, which is one of companies whose product the European Medicines Agency today announced should be approved for marketing in the EU.

EU Crunch Time For Kizfizo, Sipavibart, Coacillium And Eight Other Products

The European Medicines Agency’s human medicines committee is meeting this week due to decide whether or not to back pan-EU marketing approval for a number of new drugs.

Whirlwind Week As German Medtechs Ponder Trump Effect And Whither Domestic Government

German medtech revenue growth has slowed, profit margins are being eroded, and exporters fear harsher US market access conditions on the return to office of President-Elect Donald Trump. The week became even more momentous with news of the collapse of the German government.

EMA Schedules High-Stakes Meetings With Drug Makers

The sponsors of medicines that are nearing the end of the regulatory review cycle in the EU could this week be asked to explain why the European Medicines Agency should recommend approving their products.